| Primary |
| Hepatitis B |
74.1% |
| Chronic Hepatitis B |
10.7% |
| Hepatitis |
2.6% |
| Hepatitis C |
2.4% |
| Hepatic Cirrhosis |
1.9% |
| Hepatitis B Surface Antigen |
1.4% |
| Hypertension |
0.9% |
| Anxiety Disorder |
0.7% |
| Hepatitis B Positive |
0.7% |
| Hepatitis B Surface Antigen Positive |
0.7% |
| Renal Hypertension |
0.7% |
| Chronic Hepatitis |
0.5% |
| Nephrogenic Anaemia |
0.5% |
| Analgesic Therapy |
0.3% |
| Antiviral Treatment |
0.3% |
| Blood Pressure |
0.3% |
| Constipation |
0.3% |
| Gastritis |
0.3% |
| Hepatic Neoplasm Malignant |
0.3% |
| Hepatitis B Core Antigen Positive |
0.3% |
|
| Death |
15.7% |
| Vomiting |
13.0% |
| Normal Newborn |
7.3% |
| Pain In Extremity |
7.3% |
| Rhabdomyolysis |
6.9% |
| White Blood Cell Count Increased |
6.1% |
| Drug Exposure During Pregnancy |
3.8% |
| Hypoaesthesia |
3.8% |
| Somnolence |
3.8% |
| Weight Decreased |
3.8% |
| Myalgia |
3.4% |
| Oedema Peripheral |
3.4% |
| Viral Load Increased |
3.4% |
| Hepatic Cirrhosis |
3.1% |
| Blood Creatine Phosphokinase Increased |
2.7% |
| Maternal Exposure During Pregnancy |
2.7% |
| Myoglobin Blood Increased |
2.7% |
| Ascites |
2.3% |
| Lactic Acidosis |
2.3% |
| Nausea |
2.3% |
|
| Secondary |
| Hepatitis B |
41.2% |
| Hepatitis B Surface Antigen |
14.5% |
| Chronic Hepatitis B |
6.7% |
| Hepatic Cirrhosis |
4.8% |
| Hepatitis C |
4.2% |
| Hepatitis B Core Antigen Positive |
3.6% |
| Hepatitis B E Antigen Positive |
3.6% |
| Hepatitis B Surface Antigen Positive |
3.6% |
| Product Used For Unknown Indication |
3.6% |
| Hypertension |
2.4% |
| Renal Hypertension |
2.4% |
| Anxiety Disorder |
1.2% |
| Constipation |
1.2% |
| Hepatic Neoplasm Malignant |
1.2% |
| Nephrogenic Anaemia |
1.2% |
| Non-hodgkin's Lymphoma |
1.2% |
| Pain |
1.2% |
| Endothelial Dysfunction |
0.6% |
| Parvovirus Infection |
0.6% |
| Viral Load Increased |
0.6% |
|
| Lactic Acidosis |
10.7% |
| Hepatitis B Dna Increased |
7.1% |
| Weight Decreased |
7.1% |
| Abasia |
5.4% |
| Abdominal Pain Upper |
5.4% |
| Coagulation Factor Xi Level Decreased |
5.4% |
| Electrolyte Imbalance |
5.4% |
| Musculoskeletal Stiffness |
5.4% |
| Myoglobin Blood Increased |
5.4% |
| Myositis |
5.4% |
| Rhabdomyolysis |
5.4% |
| Viral Load Increased |
5.4% |
| Vomiting |
5.4% |
| Alpha 1 Foetoprotein Increased |
3.6% |
| Pain |
3.6% |
| Pancytopenia |
3.6% |
| Syncope |
3.6% |
| Therapeutic Response Decreased |
3.6% |
| Asthenia |
1.8% |
| Bone Formation Increased |
1.8% |
|
| Concomitant |
| Diabetes Mellitus |
33.8% |
| Hepatic Neoplasm Malignant |
22.5% |
| Ascites |
15.0% |
| Hepatitis B |
12.5% |
| Hepatocellular Carcinoma |
5.0% |
| Liver Transplant |
5.0% |
| Drug Use For Unknown Indication |
3.8% |
| Hiv Infection |
2.5% |
|
| Acute Hepatic Failure |
21.4% |
| Coagulopathy |
14.3% |
| Hypoglycaemia |
14.3% |
| Muscular Weakness |
14.3% |
| Arthralgia |
7.1% |
| Coma Hepatic |
7.1% |
| Drug Exposure During Pregnancy |
7.1% |
| Heart Rate Increased |
7.1% |
| Paraesthesia |
7.1% |
|
| Interacting |
| Coronary Artery Disease |
25.0% |
| Hepatic Cirrhosis |
25.0% |
| Hepatitis B |
25.0% |
| Myocardial Infarction |
25.0% |
|
| Arterial Thrombosis |
100.0% |
|
